Biotime SARS-CoV-2 IgG/IgM Rapid Qualitative Test got FDA EUA Authorization

Xiamen Biotime Biotechnology Co,. Ltd
Add to favorites

Biotime SARS-CoV-2 IgG/IgM Rapid Qualitative Test got FDA EUA Authorization

On July 25th, Xiamen Biotime Biotechnology Co., Ltd received the notification from FDA, telling that BIOTIME SARS-CoV-2 IgG/IgM Rapid Qualitative Test got FDA EUA authorization. This authorization proves once again that our product has passed the evaluation of international authoritative organization and been recognized by mainstream markets.

It is another breakthrough after getting CE and registration certificates in many countries including Austria, Brazil, Russia, Philippines, Chile, Peru, Honduras and Nigeria. For guaranteeing great product performance, our company is actively conducting performance verification in different authoritative institutions and has gotten brilliant evaluation results from University of Helsinki, UK Barts Health and France Amiens University.

In the near future, Biotime Biotechnology will still be committed to researching and developing new products in 2019-nCoV antigen and PCR detection to further enrich solutions against COVID-19 disease and insists on fighting against COVID-19 epidemic!

Biotime SARS-CoV-2 IgG/IgM Rapid Qualitative Test got FDA EUA Authorization